SCHEMBL20918679

SCHEMBL20918679

COc1cc(Cl)ncc1C(=O)N(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 3/20 0.47
NUDT1 P36639 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
ALDH1A1 P00352 2/20 0.38
PDE9A O76083 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
PIK3C3 Q8NEB9 1/20 0.36
GAA P10253 1/20 0.36
KDM4E B2RXH2 2/20 0.36
POLQ O75417 1/20 0.36
KCNQ3 O43525 1/20 0.36
KCNQ2 O43526 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
RORC P51449 1/20 0.36
RORB Q92753 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16804950 0.88 LRRK2 (0.38) LRRK2NUDT1L3MBTL1TDP1ALDH1A1
SCHEMBL17671060 0.83 L3MBTL1 (0.42) L3MBTL1TDP1ALDH1A1MEN1KMT2A
SCHEMBL3527742 0.83 ALDH1A1 (0.47) LRRK2L3MBTL1TDP1ALDH1A1GAA
SCHEMBL30465774 0.83 ALDH1A1 (0.47) LRRK2L3MBTL1TDP1ALDH1A1GAA
SCHEMBL20935057 0.82 MEN1 (0.43) LRRK2NUDT1PDE9AMEN1KMT2A
SCHEMBL16368532 0.81 HTT (0.46) L3MBTL1TDP1ALDH1A1MEN1KMT2A
SCHEMBL31248788 0.81 HTT (0.46) L3MBTL1TDP1ALDH1A1MEN1KMT2A
SCHEMBL18361719 0.81 LRRK2 (0.42) LRRK2NUDT1ALDH1A1PDE9AMEN1
SCHEMBL20918487 0.81 GABRP (0.44) LRRK2NUDT1ALDH1A1PDE9AMEN1
SCHEMBL1552677 0.80 KMT2A (0.41) NUDT1L3MBTL1ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 US disclosed
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2023-01-19 US disclosed
US-11440899-B2 Pyrimidine TBK/IKKe inhibitor compounds and uses thereof MERCK PATENT GMBH (DE) 2022-09-13 US disclosed
US-20210214339-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2021-07-15 US disclosed
US-20210214339-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF EMD Serono Research and Development Institute, Inc. 2021-07-15 US disclosed
EP-3697772-A1 PYRIMIDINE TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF Merck Patent GmbH (DE) 2020-08-26 EP disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed
WO-2019079375-A1 PYRIMIDINE ΤΒΚ/ΙΚΚε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed
WO-2019079373-A1 PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-04-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019491-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF DTYMK, TBKBP1, NFKBIA LRRK2 970/4885NUDT1 475/4885L3MBTL1 4128/4885
US-11440899-B2 Pyrimidine TBK/IKKe inhibitor compounds and uses thereof DTYMK, TBKBP1, NFKBIA LRRK2 970/4885NUDT1 475/4885L3MBTL1 4128/4885
US-20210214339-A1 PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF DTYMK, TBKBP1, NFKBIA LRRK2 970/4885NUDT1 475/4885L3MBTL1 4128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.